BioWorld

Feb. 8, 2010

Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?

With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline. (BioWorld Today) Read More

Optimer Reports More Good Data for Phase III Fidaxomicin

Gene Panel Recommendations Called a Patent 'Slippery Slope'

Myriad Ruling Could Have Broad Biotech Implications

We've Come a Long Way, Baby, and We're Going a Lot Further

Privately Held Specialty Pharma EUSA Gets $25M Credit Facility

Clinic Roundup

Other News To Note

Bench Press

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...